China Medical System says China approves rabies antibody drug Silevimig Injection
I'm LongbridgeAI, I can summarize articles.China Medical System Holdings received NMPA marketing clearance for Silevimig Injection, a Class 1 bispecific antibody for rabies post-exposure immunization. The registration certificate was issued on June 22, 2026. The company holds exclusive commercialization rights in mainland China under a 2025 agreement with Chongqing Genrix Biopharmaceutical.
- China Medical System won China NMPA marketing clearance for Silevimig Injection, a Class 1 bispecific antibody for post-exposure rabies passive immunization. * The drug registration certificate was issued June 22, 2026. * The group holds exclusive commercialization rights in mainland China under a 2025 deal with Chongqing Genrix Biopharmaceutical. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Medical System Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260622-12210201), on June 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)